Hamstring Versus Quadriceps Tendon Graft for MPFL Reconstruction

August 21, 2026 updated by: Mahmoud Ahmed El-Desouky, Cairo University

Comparison Between Hamstring Versus Quadriceps Tendon Graft in MPFL Reconstruction for Recurrent Patellar Dislocation

This prospective comparative study compared the clinical and radiological outcomes of medial patellofemoral ligament (MPFL) reconstruction using a hamstring tendon graft versus a quadriceps tendon graft in patients with recurrent patellar dislocation. The study included 38 patients with 40 affected knees who underwent MPFL reconstruction using either a hamstring tendon graft or a quadriceps tendon graft, according to the treating surgeon's preference. Patients were prospectively followed in two groups according to the graft used. Clinical outcomes were assessed using the Kujala, International Knee Documentation Committee (IKDC), and Tegner-Lysholm scores. Radiological assessment included patellar tilt angle and congruence angle. Postoperative complications and recurrent patellar instability were also evaluated.

Study Overview

Study Type

Observational

Enrollment (Actual)

38

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Cairo, Egypt
        • Cairo University Hospitals (Kasr Al-Ainy)

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients with recurrent patellar instability who underwent medial patellofemoral ligament reconstruction using either a hamstring tendon graft or a quadriceps tendon graft.

Description

Inclusion Criteria:

  • Patients with recurrent patellar dislocation.
  • Age from 18 to 40 years.
  • Patients indicated for isolated medial patellofemoral ligament (MPFL) reconstruction.

Exclusion Criteria:

  1. Patients with trochlear dysplasia (Dejour B-C-D).
  2. Patients with clinical evidence of mal-alignment (varus, valgus, flat foot and femoral anteversion).
  3. Patients with congenital pateller dislocation.
  4. Patella alta and patella baja.
  5. Previous quadriceps muscles operation.
  6. Patients with patellofemoral OA.
  7. Patients with hypermobility syndrome.
  8. Patients with associated pathology.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Hamstring Tendon Graft Group
Patients who underwent MPFL reconstruction using a hamstring tendon graft.
Medial patellofemoral ligament reconstruction was performed using an autologous semitendinosus tendon graft. The graft was fixed to the medial aspect of the patella and passed between layers 2 and 3 of the medial knee structures, followed by femoral fixation at the anatomical MPFL insertion.
Quadriceps Tendon Graft Group
Patients who underwent MPFL reconstruction using a quadriceps tendon graft.
Medial patellofemoral ligament reconstruction was performed using a distally based superficial quadriceps tendon graft. The graft remained attached to the superior pole of the patella, was passed between layers 2 and 3 of the medial knee structures, and was fixed at the anatomical femoral insertion of the MPFL.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Kujala score
Time Frame: 12 months postoperatively
Functional outcome assessed using the Kujala anterior knee pain scale. The score ranges from 0 to 100, with higher scores indicating better knee function and fewer patellofemoral symptoms.
12 months postoperatively

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
International Knee Documentation Committee (IKDC) Score
Time Frame: 12 months postoperatively
Knee function was assessed using the International Knee Documentation Committee (IKDC) score. Scores range from 0 to 100, with higher scores indicating better knee function.
12 months postoperatively
Tegner-Lysholm Knee Score
Time Frame: 12 months postoperatively
Knee function was assessed using the Tegner-Lysholm knee score. Scores range from 0 to 100, with higher scores indicating better knee function.
12 months postoperatively
Patellar Tilt Angle
Time Frame: 12 months postoperatively
Patellar tilt angle was measured radiologically to assess patellofemoral alignment before and after MPFL reconstruction.
12 months postoperatively
Congruence Angle
Time Frame: 12 months postoperatively
Congruence angle was measured radiologically to assess patellofemoral alignment before and after MPFL reconstruction.
12 months postoperatively
Incidence of Re-dislocation
Time Frame: 12 months postoperatively
Number of cases who experienced re-dislocation after MPFL reconstruction
12 months postoperatively

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 1, 2018

Primary Completion (Actual)

June 1, 2022

Study Completion (Actual)

June 1, 2022

Study Registration Dates

First Submitted

August 21, 2026

First Submitted That Met QC Criteria

August 21, 2026

First Posted (Actual)

August 25, 2026

Study Record Updates

Last Update Posted (Actual)

August 25, 2026

Last Update Submitted That Met QC Criteria

August 21, 2026

Last Verified

August 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe